145 related articles for article (PubMed ID: 37444567)
1. Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience.
Fianchi L; Guolo F; Marchesi F; Cattaneo C; Gottardi M; Restuccia F; Candoni A; Ortu La Barbera E; Fazzi R; Pasciolla C; Finizio O; Fracchiolla N; Delia M; Lessi F; Dargenio M; Bonuomo V; Del Principe MI; Zappasodi P; Picardi M; Basilico C; Piedimonte M; Minetto P; Giordano A; Chiusolo P; Prezioso L; Buquicchio C; Melillo LMA; Zama D; Farina F; Mancini V; Terrenato I; Rondoni M; Urbino I; Tumbarello M; Busca A; Pagano L
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444567
[TBL] [Abstract][Full Text] [Related]
2. Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL).
Di Blasi R; Cattaneo C; Lewis RE; Tumbarello M; Angelici L; Dragonetti G; Busca A; Cambò B; Candoni A; Cesarini M; Cesaro S; Delia M; Fanci R; Farina F; Garzia M; Giordano A; Martino B; Melillo L; Nadali G; Perriello V; Picardi M; Quinto AM; Salutari P; Spolzino A; Vacca A; Vetro C; Zancanella M; Nosari A; Aversa F; Pagano L;
Ann Hematol; 2018 May; 97(5):791-798. PubMed ID: 29411126
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Matthews AH; Perl AE; Luger SM; Loren AW; Gill SI; Porter DL; Babushok DV; Maillard IP; Carroll MP; Frey NV; Hexner EO; Martin ME; McCurdy SR; Stadtmauer EA; Paralkar VR; Bruno XJ; Hwang WT; Margolis D; Pratz KW
Blood Adv; 2022 Jul; 6(13):3997-4005. PubMed ID: 35507945
[TBL] [Abstract][Full Text] [Related]
4. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
Roboz GJ; Larson ML; Rubenstein SE; Solomon SR; Schiller GJ; An Q; Chiarella M; Louie AC; Lin TL
Leuk Lymphoma; 2020 May; 61(5):1188-1194. PubMed ID: 32102577
[TBL] [Abstract][Full Text] [Related]
5. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.
Kolitz JE; Strickland SA; Cortes JE; Hogge D; Lancet JE; Goldberg SL; Villa KF; Ryan RJ; Chiarella M; Louie AC; Ritchie EK; Stuart RK
Leuk Lymphoma; 2020 Mar; 61(3):631-640. PubMed ID: 31760835
[TBL] [Abstract][Full Text] [Related]
6. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE
Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279
[TBL] [Abstract][Full Text] [Related]
7. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Hospital Length of Stay and Supportive Care Utilization Between Patients Treated with CPX-351 and 7+3 for Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
Price K; Cao Z; Lipkin C; Profant D; Robinson S
Clinicoecon Outcomes Res; 2022; 14():21-34. PubMed ID: 35035224
[TBL] [Abstract][Full Text] [Related]
9. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
[TBL] [Abstract][Full Text] [Related]
10. High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study.
Cattaneo C; Marchesi F; Terrenato I; Bonuomo V; Fracchiolla NS; Delia M; Criscuolo M; Candoni A; Prezioso L; Facchinelli D; Pasciolla C; Del Principe MI; Dargenio M; Buquicchio C; Mitra ME; Farina F; Borlenghi E; Nadali G; Gagliardi VP; Fianchi L; Sciumè M; Menna P; Busca A; Rossi G; Pagano L
J Fungi (Basel); 2022 May; 8(6):. PubMed ID: 35736066
[TBL] [Abstract][Full Text] [Related]
11. Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia.
Felsenstein S; Orgel E; Rushing T; Fu C; Hoffman JA
Pediatr Infect Dis J; 2015 Apr; 34(4):e78-84. PubMed ID: 25764103
[TBL] [Abstract][Full Text] [Related]
12. CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.
Lee D; Jain AG; Deutsch Y; Eatrides J; Chan O; Padron E; Kuykendall A; Komrokji R; Lancet J; Sallman D; Talati C; Sweet K
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):774-779. PubMed ID: 35760672
[TBL] [Abstract][Full Text] [Related]
13. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Chiche E; Rahmé R; Bertoli S; Dumas PY; Micol JB; Hicheri Y; Pasquier F; Peterlin P; Chevallier P; Thomas X; Loschi M; Genthon A; Legrand O; Mohty M; Raffoux E; Auberger P; Caulier A; Joris M; Bonmati C; Roth-Guepin G; Lejeune C; Pigneux A; Vey N; Recher C; Ades L; Cluzeau T
Blood Adv; 2021 Jan; 5(1):176-184. PubMed ID: 33570629
[TBL] [Abstract][Full Text] [Related]
14. Infections in acute myeloid leukemia: an analysis of 382 febrile episodes.
Gupta A; Singh M; Singh H; Kumar L; Sharma A; Bakhshi S; Raina V; Thulkar S
Med Oncol; 2010 Dec; 27(4):1037-45. PubMed ID: 19830601
[TBL] [Abstract][Full Text] [Related]
15. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
Bradley AM; Deal AM; Buie LW; van Deventer H
Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia.
Villa KF; Ryan RJ; Chiarella M; Louie AC
J Med Econ; 2020 Jul; 23(7):714-720. PubMed ID: 32188326
[No Abstract] [Full Text] [Related]
17. 'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.
Del Principe MI; Dragonetti G; Verga L; Candoni A; Marchesi F; Cattaneo C; Delia M; Potenza L; Farina F; Ballanti S; Decembrino N; Castagnola C; Nadali G; Fanci R; Orciulo E; Veggia B; Offidani M; Melillo L; Manetta S; Tumbarello M; Venditti A; Busca A; Aversa F; Pagano L;
J Antimicrob Chemother; 2019 Apr; 74(4):1062-1068. PubMed ID: 30649413
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
Rautenberg C; Stölzel F; Röllig C; Stelljes M; Gaidzik V; Lauseker M; Kriege O; Verbeek M; Unglaub JM; Thol F; Krause SW; Hänel M; Neuerburg C; Vucinic V; Jehn CF; Severmann J; Wass M; Fransecky L; Chemnitz J; Holtick U; Schäfer-Eckart K; Schröder J; Kraus S; Krüger W; Kaiser U; Scholl S; Koch K; Henning L; Kobbe G; Haas R; Alakel N; Röhnert MA; Sockel K; Hanoun M; Platzbecker U; Holderried TAW; Morgner A; Heuser M; Sauer T; Götze KS; Wagner-Drouet E; Döhner K; Döhner H; Schliemann C; Schetelig J; Bornhäuser M; Germing U; Schroeder T; Middeke JM
Blood Cancer J; 2021 Oct; 11(10):164. PubMed ID: 34608129
[TBL] [Abstract][Full Text] [Related]
19. Levofloxacin for febrile neutropenia prophylaxis in acute myeloid leukemia patients associated with reduction in hospital admissions.
Lee SSF; Fulford AE; Quinn MA; Seabrook J; Rajakumar I
Support Care Cancer; 2018 May; 26(5):1499-1504. PubMed ID: 29170868
[TBL] [Abstract][Full Text] [Related]
20. Validation of AML-score in Older Adults Receiving CPX-351 Intensive Induction Chemotherapy for Treatment of Secondary Acute Myeloid Leukemia.
Schmucker AM; Leiby BE; Wilde L
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e206-e212. PubMed ID: 34686446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
